Genomic and Longitudinal Risk Assessment in Smoldering Multiple Myeloma

In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss how emerging approaches such as genomic profiling and longitudinal risk assessment may help refine risk stratification in smoldering multiple myeloma. Dr. Usmani explains that traditional models provide an important baseline snapshot of risk using clinical and laboratory parameters. However, these models may not fully capture the biological diversity of the disease. He notes that genomic profiling can offer additional insight into disease biology by identifying molecular abnormalities that may signal a higher likelihood of progression. Dr. Usmani also emphasizes the importance of monitoring patients over time, describing how changes in biomarkers or disease parameters can provide a more dynamic understanding of progression risk. Dr. Vincent Rajkumar adds that integrating genomic information with established clinical risk models may improve the ability to identify patients who are most likely to progress. Together, the panel highlights how evolving tools may complement traditional assessments in smoldering multiple myeloma.